CSPC Pharmaceutical Group Limited (HK:1093)
:1093
Want to see HK:1093 full AI Analyst Report?
1093 Stock Chart & Stats
HK$8.96
HK$0.04(0.91%)
At close: 4:00 PM EST
HK$8.96
HK$0.04(0.91%)
Day’s Range― - ―
52-Week RangeHK$6.64 - HK$11.63
Previous CloseN/A
Volume61.16M
Average Volume (3M)135.86M
Market Cap
HK$83.28B
Enterprise ValueHK$68.44B
Total Cash (Recent Filing)HK$8.87B
Total Debt (Recent Filing)HK$641.38M
Price to Earnings (P/E)18.9
Beta0.79
Next Earnings
Aug 26, 2026EPS Estimate
0.19Next Dividend Ex-DateN/A
Dividend Yield2.7%
Share Statistics
EPS (TTM)0.34
Shares Outstanding11,522,452,000
10 Day Avg. Volume105,139,995
30 Day Avg. Volume135,859,703
Financial Highlights & Ratios
PEG Ratio-1.94
Price to Book (P/B)2.90
Price to Sales (P/S)3.80
P/FCF Ratio24.15
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$11.70Price Target Upside30.54% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering15
EPS Forecast (FY)0.65
Revenue Forecast (FY)HK$31.28B
Bulls Say, Bears Say
Bulls Say
Extremely Low LeverageA debt-to-equity of ~0.02 gives CSPC durable financial flexibility: it can fund R&D, maintain production, and pursue opportunistic M&A without refinancing risk. Low leverage also cushions cash flow swings and reduces solvency risk over a multi-quarter horizon.
Strong 2025 Cash GenerationA sizable free cash flow rebound in 2025 materially improves internal funding for commercialization, R&D and shareholder returns. Sustained FCF at this level would enhance self-funding of pipeline progression and reduce reliance on external capital over coming quarters.
High Gross And Solid Operating MarginsElevated gross margins and mid-teens operating/net margins reflect product pricing power and a differentiated portfolio. These margin levels support durable profitability and cash generation even if top-line growth is modest, helping sustain investments in drug development.
Bears Say
Recent Revenue Weakness And Slow RecoveryTwo years of revenue decline followed by only low-single-digit growth implies weakening top-line momentum. Sluggish sales recovery limits operating leverage, slows payback on R&D and commercialization spending, and makes sustained margin restoration more difficult over several quarters.
Margin Compression And Falling ROEMaterial margin compression and lower ROE indicate reduced efficiency in turning sales into shareholder returns versus prior years. That trend can persist absent stronger revenue growth or cost restructuring, limiting improvement in returns on invested capital over the medium term.
Volatile Cash Flow And Limited Coverage VisibilityAlthough 2025 FCF was strong, prior volatility and missing coverage metrics reduce confidence in predictability of cash available for R&D, dividends or buybacks. This unpredictability complicates long-term planning and raises risk for capital allocation decisions over the next several quarters.
CSPC Pharmaceutical Group News
1093 FAQ
What was CSPC Pharmaceutical Group Limited’s price range in the past 12 months?
CSPC Pharmaceutical Group Limited lowest stock price was HK$6.64 and its highest was HK$11.63 in the past 12 months.
What is CSPC Pharmaceutical Group Limited’s market cap?
CSPC Pharmaceutical Group Limited’s market cap is HK$83.28B.
When is CSPC Pharmaceutical Group Limited’s upcoming earnings report date?
CSPC Pharmaceutical Group Limited’s upcoming earnings report date is Aug 26, 2026 which is in 73 days.
How were CSPC Pharmaceutical Group Limited’s earnings last quarter?
CSPC Pharmaceutical Group Limited released its earnings results on May 27, 2026. The company reported HK$0.087 earnings per share for the quarter, missing the consensus estimate of HK$0.133 by -HK$0.046.
Is CSPC Pharmaceutical Group Limited overvalued?
According to Wall Street analysts CSPC Pharmaceutical Group Limited’s price is currently Undervalued.
Does CSPC Pharmaceutical Group Limited pay dividends?
CSPC Pharmaceutical Group Limited pays a Semiannually dividend of HK$0.15 which represents an annual dividend yield of 2.7%. See more information on CSPC Pharmaceutical Group Limited dividends here
What is CSPC Pharmaceutical Group Limited’s EPS estimate?
CSPC Pharmaceutical Group Limited’s EPS estimate is 0.19.
How many shares outstanding does CSPC Pharmaceutical Group Limited have?
CSPC Pharmaceutical Group Limited has 11,522,452,000 shares outstanding.
What happened to CSPC Pharmaceutical Group Limited’s price movement after its last earnings report?
CSPC Pharmaceutical Group Limited reported an EPS of HK$0.087 in its last earnings report, missing expectations of HK$0.133. Following the earnings report the stock price went down -5.376%.
Which hedge fund is a major shareholder of CSPC Pharmaceutical Group Limited?
Currently, no hedge funds are holding shares in HK:1093
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
CSPC Pharmaceutical Group Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$11.70 (30.54% Upside)
HK$11.70 (30.54% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
33.69%
12-Months-Change
Fundamentals
Return on Equity
12.19%
Trailing 12-Months
Asset Growth
9.88%
Trailing 12-Months
Company Description
CSPC Pharmaceutical Group Limited
CSPC Pharmaceutical Group Limited, primarily an investment holding entity, is dedicated to the development, production, and distribution of pharmaceutical goods. Its operations span the globe, with a significant presence in the People's Republic of China, across Asia, in the Americas, and throughout Europe. The company structures its business activities into three main divisions: Finished Drugs, Bulk Products, and Functional Food and Other ventures. The company's extensive portfolio of finished drugs encompasses treatments for a wide range of conditions. Key offerings include NBP (available as soft capsules and injections) for acute ischemic stroke, and Oulaining (capsules and injections) addressing mild to moderate memory and cognitive impairments. For neurological disorders, Enxi targets adult idiopathic Parkinson's disease. In oncology, Duomeisu treats lymphoma, multiple myeloma, ovarian and breast cancers, alongside other malignant tumors, while Jinyouli aids in preventing chemotherapy-induced leucopenia and infections, and Keaili is prescribed for breast cancer. Further therapeutic areas covered by CSPC include various infections, with products such as Shuluoke, Nuomoling, Weihong, and Xinweihong. Cardiovascular health is addressed by Xuanning for hypertension and Encun to avert atherosclerotic thrombosis events. Qixiao provides relief for upper respiratory tract infections, and diabetes management is supported by Linmeixin and Shuanglexin. Bone health solutions include Gubang and Gubangjia for postmenopausal osteoporosis. Additionally, Gaoshunsong offers relief for a broad spectrum of inflammatory and pain-related conditions, including arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursitis, tenosynovitis, acute gout, dysmenorrhea, toothache, postoperative pain, lower back pain, sprains, strains, and other soft tissue injuries. Other notable products include Debixin for various types of ulcers and Qimaite for acute and chronic pain management. Beyond finished pharmaceuticals, CSPC also supplies active pharmaceutical ingredients (APIs) like antibiotics, vitamin C, and caffeine. The company further diversifies into functional foods, glucose products, and provides healthcare services. Originally established in 1992, the company initially operated under the name China Pharmaceutical Group Limited before adopting its current designation, CSPC Pharmaceutical Group Limited, in March 2013. Its primary corporate office is situated in Shijiazhuang, within the People's Republic of China.
1093 Stock 12 Month Forecast
Average Price Target
HK$11.70
▲(30.54% Upside)
Technical Analysis
Sino Biopharmaceutical
―
China Medical System Holdings
―
Guangzhou Baiyunshan Pharmaceutical Holdings Company
―
Shanghai Pharmaceuticals Holding Co
―
China Resources Pharmaceutical Group Ltd.
―
Options Prices
Currently, No data available
---